INS and type 2 diabetes mellitus: Basal insulin analogs have the advantage of lower risk of hypoglycemia in patients with type 1 and type 2 diabetes and also improved glycemic control.40 Cost-related medications non-adherence is associated with higher rate of all-cause mortality and cardiovascular complications among newly diagnosed type 2 diabetes mellitus patients.41 Although more adherent patients incur higher pharmacy costs, these are generally offset by savings in other areas such as costs of hospital admissions and physicians’ visits.42